← Human Trials & Peer-Reviewed Studies
[Effects of recombinant human growth hormone on serum lipid in aged male patients with chronic heart failure].
Plain-language guide to PMID 25244793 (2014): randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
Key Facts
- PMID
- 25244793
- Journal
- Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology
- Year
- 2014
- Study type
- Randomized Controlled Trial
- Authors
- Ding Y et al. (2 authors)
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.
To investigate the effects of recombinant human growth hormone on serum lipid in aged male patients with chronic heart failure (CHF).
Who Took Part
By PubMed's age tags, the people studied were older adults, men only.
Eighty seven patients with chronic heart failure(> or = 60 years old) were randomly divided into 2 groups: the CHF control group (n = 46) who received regular therapy and the CHF experimental group (n = 41) who received regular therapy and recombinant human growth hormone.
The detection of serum growth hormone (GH), insulin-like growth factor (IGF-1), total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C) was carried out before and after treatment in the participants.
How the Study Was Run
The researchers set it up as a randomized study.
The participants were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.
Another group was normal control group (n = 10).
What Was Measured
PubMed files the paper under topics including Chronic Disease, Heart Failure, Human Growth Hormone, Lipids and Recombinant Proteins.
What This Means in Plain Language
The paper is a randomized study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
Its findings take up roughly 11 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2014 (Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology), a journal based in China.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.
Our Notes on the Compound
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.